This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters (NV-US-04-001)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: June 17, 2008
Last updated: June 19, 2008
Last verified: May 2008
Catheter associated urinary tract infection is one of the most common types of catheter acquired infections and adds greatly to patient morbidity, mortality and medical cost. Urinary catheters may readily acquire biofilms when inserted. The longer the catheter remains in place, the greater the tendency of these organisms to develop biofilms and result in urinary tract infections, which are difficult to treathe UroShield System is intended to prevent bacterial biofilm formation by means of the Active NanoShield technology it has developed. A number of scientific concepts and principles shown in prior studies have shown some promising results in the treatment of biofilm based sequele using ultrasound energy. The NanoShield technological basis of the UroShield System has taken these concepts to a level where acoustical waves in the ultrasound range can be created by low cost disposable actuators which actually create a physical coating on all of the surfaces of the catheter thereby interfering with the attachment of bacteria which is the initial step in biofilm formation.

Urinary Tract Infection

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Phase II Prospective Comparison Randomized Placebo Controlled Double Blind Study to Evaluate the Efficacy of the UroShieldTM Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Primary Outcome Measures:
  • Reduction in pain and discomfort in patients with PCN catheters, improvement of catheter's patency. [ Time Frame: 28 days for one subject overall 1 year ]

Secondary Outcome Measures:
  • Renal function improvement [ Time Frame: 28 days per pateint overall 1 year ]

Biospecimen Retention:   None Retained
urine culture

Estimated Enrollment: 24
Study Start Date: August 2008
Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study

Detailed Description:

The UroShield™ System is comprised of 2 main components:· The Disposable UroShield Z-Patch - a disposable small lightweight patch that is attached to the PCN catheter, while its opposite side is attached directly to the patient's skin at the site of catheter entry. The patch has twofold function:

  1. it receives energy and a signal from the UroShield Driver allowing it to generate the ultrasonic waves;
  2. it acts as a fixation device for the PCN catheter.· The UroShield Driver - an external driver unit that is attached to the UroShield patch and contains batteries to power the system and electronics that control the patch unit

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All Patients requiring percoutaneous nephrostome drainage for period for more then 4 weeks

Inclusion Criteria:

  • Patients requiring percoutaneous nephrostome
  • First insertion

Exclusion Criteria:

  • Blood coagulation disorders
  • Trauma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00702286

Contact: Yoram I Siegel, MD 972-8-9779400

Assaf Harofeh MC Not yet recruiting
Zerifin, Isarel, Israel, 40700
Contact: Yoram I Siegel, MD    972-8-9779400    yoram.siegel   
Contact: Amir Peer, MD    972-8-9779483      
Principal Investigator: Yoram I Siegel, MD         
Sub-Investigator: Yenon Roterman, MD         
Sub-Investigator: Amir Copper, MD         
Sub-Investigator: Amir Peer, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: Yoram I Siegel, MD Assaf Harofeh MC
  More Information

Responsible Party: Yoram Siegel MD Head of endourolgy unit assaf harofeh MC, Assaf Harofeh MC Identifier: NCT00702286     History of Changes
Other Study ID Numbers: 75/08
Study First Received: June 17, 2008
Last Updated: June 19, 2008

Keywords provided by Assaf-Harofeh Medical Center:
Surface acoustic ultrasound
biofilm formation
percoutaneous nephrostomy tube
Patients requiring per coetaneous drainage due to urinary
tract obstruction
To evaluate the efficacy of surface acoustic wave in
reducing pain and improving drainage

Additional relevant MeSH terms:
Urinary Tract Infections
Urologic Diseases processed this record on June 23, 2017